Neoadjuvant chemotherapy in pancreatic cancer: Innovative, but still difficult

British Journal of Cancer

Volumn 111, Issue 8, 2014, Pages 1675-1676

  Boeck, S ^a   Haas, M ^a   Ormanns, S ^b   Kruger, S ^a   Siveke, J T ^c   Heinemann, V ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; ANIMAL; FEMALE; FIBROBLAST; HUMAN; MALE; PANCREATIC NEOPLASMS; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FIBROBLASTS; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 84908867162     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.60     Document Type: Letter

References (7)

1. Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Munoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M (2013) Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 109: 926-933.
2. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V (2006) Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 70: 255-264.
3. Heinemann V, Haas M, Boeck S (2013) Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 24: 2484-2492.
4. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118: 5749-5756.
5. Katz MH, Varadhachary GR, Fleming JB,Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB (2010) Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17: 1794-1801.
6. Maithel SK, Maloney S, Winston C, Gönen M, D'Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF, Allen PJ (2008) Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 15: 3512-3520.
7. Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K, Yano M (2010) Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 251: 461-469.